

Basel Breast Consortium

TRICYCLE LUNCHTIME SEMINAR

Identification of mechanisms of resistance to Fulvestrant plus Ribociclib in ER+/HER2advanced breast cancer

Jorge Gomez, DBM, University Hospital Basel


Immunecheckpoint Blockade in Breast Cancer – Current and Future standard of Care

Anton Oseledchyk, University Hospital, Basel

Imlunestrant, an oral selective estrogen receptor degrader, in estrogen receptor-positive advanced breast cancer

Roohi Ismail-Khan, Eli Lilly, Switzerland

Tuesday, December 13, 2022, 12:30



Seminar room 2nd floor, ZLF - Hebelstrasse 20, Basel

Lunch buffet provided at 12:00 in front of the seminar room

www.baselbc.org





- Universitätsspital Basel